Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

State of the Science Summit - Gynecologic Cancers: Chaired by Aditya Bardia, MD, MPH and Laura Spring, MD

December 1st 2023

State of the Science Summit - Gynecologic Cancers: Chaired by Aditya Bardia, MD, MPH and Laura Spring, MD

Closing Thoughts on Evolving Antibody-Drug Conjugate Landscape

December 1st 2023

The expert panel concludes the program with key takeaways and closing thoughts on the evolving antibody-drug conjugate space.

Dr Sparano on Advances in Breast Cancer Screening, Treatment, and Drug Development

December 1st 2023

Joseph A. Sparano, MD, FACP, discusses developments in breast cancer diagnosis and treatment.

FDA Grants Fast Track Designation to Zotatifin Plus Fulvestrant/Abemaciclib in ER+/HER2– Breast Cancer

November 30th 2023

The FDA has granted fast track designation to zotatifin for use in combination with fulvestrant and abemaciclib as second- or third-line therapy for the treatment of patients with estrogen receptor-positive, HER2-negative advanced or metastatic breast cancer with disease progression following treatment with endocrine therapy and a CDK4/6 inhibitor.

ADC Choices Require Discretion in HER2-Negative MBC

November 30th 2023

With multiple antibody drug conjugate options now available for patients with HER2-negative metastatic breast cancer, clinicians must consider a variety of factors when selecting and sequencing therapies.

State of the Science Summit - Breast Cancer: Chaired by Maryam Lustberg, MD, MPH

November 28th 2023

State of the Science Summit - Breast Cancer: Chaired by Maryam Lustberg, MD, MPH

Reviewing Best Practices in the Surgical Management of Breast Cancer: Opportunities for Stage IV Disease

November 28th 2023

In this fourth episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss how to appropriately manage patients with stage IV breast cancer and outline when surgical approaches may be appropriate for this population.

Capivasertib and Fulvestrant for Patients with Aromatase Inhibitor-resistant Hormone Receptor-positive/Human Epidermal Growth Factor Receptor 2-negative Advanced Breast Cancer: Results from the Phase III CAPItello-291 Trial

November 28th 2023

Hope Rugo, MD reviews key data from the CAPItello-291 phase 3 trial recently presented at the San Antonio Breast Cancer Symposium in December 2022.

Dr Torres on Treatment With ADCs in Breast Cancer

November 28th 2023

Mylin A. Torres, MD, discusses using antibody-drug conjugates (ADCs) to treat patients with breast cancer.

Dr Ma on the Use of AKT Inhibitors vs PI3K Inhibitors in Breast Cancer

November 27th 2023

Cynthia Ma, MD, PhD, discusses the use of AKT inhibitors vs PI3K inhibitors in breast cancer.

Educating Community Specialists on Evolving Treatment Landscape

November 24th 2023

Experts in breast, lung, and gastric malignancies provide insights on multidisciplinary care in oncology and educating community specialists.

Future Outlook for Treating Breast and Lung Cancers

November 24th 2023

Medical oncologists discuss prospects and challenges in the breast and lung cancer treatment landscapes.

Novel Treatment Approaches Under Investigation for HER2+ mBC

November 23rd 2023

Joseph Gligorov, MD, emphasizes the impact of trastuzumab deruxtecan in HER2-positive breast cancer and explores its potential in HER2-low populations, and envisions a future where ADCs and immunotherapy will have a vital role in treatment, particularly in triple-negative breast cancer.

Reviewing Best Practices in the Surgical Management of Breast Cancer: Key Advances

November 21st 2023

In this third episode of OncChats: Reviewing Best Practices in the Surgical Management of Breast Cancer, Gladys Giron, MD, FACS, and Cristina Lopez-Peñalver, MD, discuss key advancements made in the surgical treatment of patients with breast cancer.

FDA Approves Companion Diagnostic for Capivasertib Plus Fulvestrant in Advanced HR+/HER2–Breast Cancer

November 21st 2023

The FDA has approved the FoundationOne® CDx for use as a companion diagnostic to identify patients with advanced hormone receptor–positive, HER2-negative advanced breast cancer who may be eligible for treatment with the combination of capivasertib and fulvestrant.

Dr Kalinsky on Remaining Treatment Questions in Breast Cancer

November 17th 2023

Kevin Kalinsky, MD, MS, discusses key takeaways from the 2023 Bridging the Gaps in Breast Cancer meeting, highlighting questions that continue to persist in the treatment of breast cancer.

Dr Basho on Treatment Considerations With ADCs in Breast Cancer

November 17th 2023

Reva K Basho, MD, discusses the use of antibody-drug conjugates across the spectrum of breast cancer subtypes at the 2023 Bridging the Gaps in Breast Cancer meeting.

Future Directions in Gastric Cancer Treatment

November 17th 2023

Specialists in gastric cancer look to the future treatment landscape and review ongoing research in the disease space.

Treatment Considerations With TROP2-Targeted Therapy

November 17th 2023

Clinical insights on best practices for treating patients with TROP2-targeted therapy.

FDA Approves Capivasertib Plus Fulvestrant in Advanced HR+/HER2– Breast Cancer With PIK3CA, AKT1, or PTEN Alterations

November 16th 2023

The FDA has approved capivasertib plus fulvestrant for the treatment of patients with HR-positive, HER2-negative, locally advanced or metastatic breast cancer harboring 1 or more PIK3CA, AKT1, or PTEN alterations, following progression on at least 1 endocrine-based regimen in the metastatic setting or recurrence on or within 12 months of completing adjuvant therapy.